Fundraising FoxhealthOme
Huntsville, US · Founded 2021 · Delaware corporation
Find your way into healthOme
Sign up to see every warm intro you have to healthOme
- Paths you didn't know you had: your email and LinkedIn already hold routes to the healthOme team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HealthŌme combines insurance with health navigation services to improve how patients access, finance, and receive precision healthcare.
Founders & leadership
Board
ST
Spencer TallBoard director
BC
Brittany ClementsBoard director
AM
Anne Melissa DowlingBoard director
Reported raises · per SEC filings
Form D private placements$9.9M disclosed across 2 rounds · 2023–2024
▶$2MraisedDec 2024 · 2 investors · OtherRule 506(b)
▶$2MraisedDec 2024 · 2 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- David StertzerExecutive Officer, Director
- Brittany ClementsDirector
- Spencer TallDirector
- Anne Melissa DowlingDirector
- Camilo MoncadaExecutive Officer
- Terri KinlochExecutive Officer
- Kimberly ScottExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Proceeds to insiders
- $925K
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$7.9MraisedMay 2024 · 10 investors · OtherRule 506(b)
▶$7.9MraisedMay 2024 · 10 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Spencer TallDirector
- Brittany ClementsDirector
- Terri KinlochExecutive Officer
- Anne Melissa DowlingDirector
- Camilo MoncadaExecutive Officer
- David StertzerExecutive Officer, Director
- Kimberly ScottExecutive Officer
- Offering amount
- $8.4M
- Amount sold
- $7.9M
- Minimum investment
- $100K
- Proceeds to insiders
- $925K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 10
MyomeMyOme provides genomic insights and clinical genetic screening reports to help individuals and healthcare providers assess risks for hereditary conditions and make informed health decisions.
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
OneOmeOneOme is a precision medicine company that provides pharmacogenomics testing and analytics to healthcare providers, helping them optimize medication selection based on patients' genetic profiles. Co-founded by Mayo Clinic, the company serves healthcare teams and institutions globally seeking to improve patient outcomes and reduce costs through personalized medication decisions.
Alterome Therapeutics, Inc.Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic. It focuses on hard-to-drug cancer targets such as mutant KRAS and mutant AKT E17K across malignancies including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancers.
Noveome BiotherapeuticsNoveome is a clinical-stage biopharmaceutical company developing ST266, a multi-targeted secretome containing hundreds of biologically active proteins designed for neuroprotection, inflammation modulation, and tissue healing. The company is investigating ST266's potential across ophthalmology, neurology, dermatology, and other therapeutic areas.
FreenomeFreenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases. The company serves healthcare providers and patients seeking preventive cancer screening solutions.
NucleomeNucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets. The company builds a data atlas of immune system dysregulation to enable development of genetically-informed therapeutics for inflammatory conditions.
SensomeSensome develops medical technology solutions at the intersection of engineering and life sciences, focusing on healthcare applications.
CellanomeCellanome develops a live-cell analysis platform using CellCage technology to create controlled microenvironments that enable researchers to observe cell behavior and molecular changes over time. The platform generates structured multimodal data for life sciences researchers and biopharma companies focused on oncology, neuroscience, immunology, and aging research.
EtiomeEtiome develops stage-specific medicines by applying single-cell omics and artificial intelligence to map disease progression and identify disease-modifying targets at early biological inflection points for preemptive intervention. Founded in 2021 out of Flagship Pioneering's Preemptive Health and Medicine initiative, the biotech company focuses on treating or reversing disease before it advances to later stages.
Companies working in the same space as healthOme.
Frequently asked questions
- What does healthOme do?
- HealthŌme combines insurance with health navigation services to improve how patients access, finance, and receive precision healthcare.
- How much funding has healthOme raised?
- healthOme has disclosed $9.9M raised across 2 rounds.
- Where is healthOme headquartered?
- healthOme is headquartered in Huntsville, US.